Avacta Group


£30.5m market cap

26.25p last close

Avacta is focused on the development of its Affimer technology for use in therapeutic and diagnostic/reagent applications. Assets include AVA004 (PD-L1), AVA021 (PD-L1/LAG-3) and AVA004/100 (PD-L1/I-DASH).

Investment summary

Avacta is developing its proprietary Affimer platform in therapeutic and diagnostic applications. Affimers have many of the epitope-binding characteristics of antibodies, but with a much smaller molecular size (and cost of goods). In addition, Affimers can be modified as bispecifics, drug-antibody conjugates (DACs) or half-life extenders, or combinations thereof. Avacta’s first Affimer product to go into into the clinic towards the end of 2020 is AVA004, an anti-PD1-L1 Affimer that is expected to prove safety and efficacy principles for Affimers that contain AVA004 as a component, such as the bispecific PD-L1/LAG3 Affimer, AVA021. Avacta has collaborations with LG Chem and Moderna, while the animal health and diagnostic applications of Affimers provide incremental revenues.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2017A 2.7 N/A (7.9) (9.8) N/A N/A
2018A 2.8 N/A (10.4) (13.5) N/A N/A
2019E 3.2 N/A (12.3) (9.0) N/A N/A
2020E 5.2 N/A (12.4) (9.0) N/A N/A
Industry outlook

The rise of biosimilar drugs, in Europe at least, has highlighted the need for new biological drugs by companies that previously developed protein drugs like monoclonal antibodies. These potential partners, as well as those which already have a branded antibody product, would be keen adopters of the Affimer technology that gives them second-generation bispecifics and DACs.

Last updated on 25/07/2019
Share price graph
Balance sheet
Forecast net cash (£m) 5
Forecast gearing ratio (%) N/A
Price performance
Actual (11.0) (19.2) (31.8)
Relative* (12.2) (19.3) (29.6)
52-week high/low 47.0p/21.2p
*% relative to local index
Key management
Alastair Smith CEO
Tony Gardiner CFO